Portal de investigación
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- del Muro, XG
- Gallardo, E
- Carbonero, IG
- Lainez, N
- Mendez, MJ
- Maroto, P
- de Olza, MO
- Puente, J
- Rubio, J
- Santander, C
- Suarez, C
- Estevez, SV
- Castellano, D
Grupos
Abstract
Clear-cell renal cell carcinoma (RCC) is the most common kidney cancer. New treatment options of localized RCC recently incorporated include laparoscopic surgery, nephron-sparing surgery, ablative techniques and active surveillance. But 50 % of patients may develop disease recurrence attributable to subclinical metastases. In these cases, and considering the low benefits of chemotherapy, new targeted therapies such as tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors have been developed as first- and second-line treatment. Both sunitinib and pazopanib are TKIs that constitute the first-line treatment option in patients with metastatic RCC. As second-line treatment, sequential therapy with a second TKI or a mTOR inhibitor is recommended. This review has collected together a series of recommendations issued by the Spanish Oncology Genitourinary Group with the aim of facilitating the treatment of these patients. Each recommendation is accompanied by the level of evidence and grade of recommendation on the basis of the available data.
Datos de la publicación
- ISSN/ISSNe:
- 0344-5704, 1432-0843
- Tipo:
- Review
- Páginas:
- 1095-1107
- Factor de Impacto:
- 1,141 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
CANCER CHEMOTHERAPY AND PHARMACOLOGY SPRINGER
Documentos
- No hay documentos
Filiaciones
Keywords
- Diagnosis; Nephrectomy; Renal cell carcinoma; Tyrosine kinase inhibitor
Proyectos asociados
ESTUDIO RETROSPECTIVO DEL MANEJO DE PACIENTES CON CANCER DE PROSTATA HORMONORESISTENTE AVANZADO. ESTUDIO ESPRO.
Investigador Principal: GASPAR REYNES MUNTANER
SAN-DOC-2010-02 . 2011
ENSAYO CLINICO ABIERTO, FASE II DE TRATAMIENTO NEO-ADYUVANTE DE SUNITINIB (SU11248) PREVIO AL TRATAMIENTO CON IRRADIOACION Y CONCOMITANTE A LA MISMA EN PACIENTES CON GLIOBLASTOMA RPA V-VI Y SOLO BIOPSIA
Investigador Principal: GASPAR REYNES MUNTANER
GENOM-008 . 2009
CLORURO DE RADIO-223 (ALPHARADIN) EN PACIENTES CON CÁNCER DE PRÓSTATA RESISTENTE A LA CASTRACIÓN (HORMONORRESISTENTE) CON METÁSTASIS ÓSEA.
Investigador Principal: GASPAR REYNES MUNTANER
BAY88-8223/16216 . 2013
ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PF299804, UN INHIBIDOR PAN-HER IRREVERSIBLE, EN PACIENTES CON GLIOBLASTOMA RECURRENTE CON AMPLIFICACIÓN DE EGFR O PRESENCIA DE LA MUTACIÓN EGFRVIII .
Investigador Principal: GASPAR REYNES MUNTANER
GEINO-11 . 2012
ENSAYO CLINICO, FASE II ALEATORIZADO DE TRATAMIENTO NEO-ADYUVANTE CON DOS CICLOS DE TEMOZOLOMIDA A DOSIS EXTENDIDAS, PREVIOS AL TRATAMIENTO CON TEMOZOLOMIDA MAS IRRADIACION Y POSTERIOR ADYUVANCIA CON TEMOZOLOMIDA VERSUS MISMO TRATAMIENTO CON BEVACIZUMAB
Investigador Principal: GASPAR REYNES MUNTANER
GENOM-009 . 2010
Cita
del Muro XG,Gallardo E,Carbonero IG,Lainez N,Mendez MJ,Maroto P,de Olza MO,Puente J,Reynes G,Rubio J,Santander C,Suarez C,Estevez SV,Castellano D. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2014. 73(6):p. 1095-1107. IF:2,769. (2).